IOVA
Iovance Biotherapeutics, Inc.Healthcare · $6.6B market cap
Verdict
We can't put a fair value on IOVA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow IOVA
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 1, 2026: no open-market purchases and 12 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
Puri Raj K.
Chief Regulatory Officer · 2026-09-08
Tax withholding
$39K
Puri Raj K.
Chief Regulatory Officer · 2026-09-08
Option exercise
9,766 shares
BILINSKY IGOR
Chief Operating Officer · 2026-09-08
Tax withholding
$35K
BILINSKY IGOR
Chief Operating Officer · 2026-09-08
Option exercise
7,813 shares
Vogt Frederick G
Interim CEO & General Counsel · 2026-09-08
Tax withholding
$58K
Show all 12 other filingsShow fewer
Vogt Frederick G
Interim CEO & General Counsel · 2026-09-08
Option exercise
15,626 shares
BILINSKY IGOR
Chief Operating Officer · 2026-09-01
Tax withholding
$37K
BILINSKY IGOR
Chief Operating Officer · 2026-09-01
Option exercise
8,789 shares
Puri Raj K.
Chief Regulatory Officer · 2026-09-01
Tax withholding
$21K
Puri Raj K.
Chief Regulatory Officer · 2026-09-01
Option exercise
5,470 shares
Vogt Frederick G
Interim CEO & General Counsel · 2026-09-01
Tax withholding
$147K
Vogt Frederick G
Interim CEO & General Counsel · 2026-09-01
Option exercise
41,669 shares
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works